Tel: 0113 4264300 | info@arterius.co.uk

PRODUCTS

PRODUCTS

Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES); come in a range of sizes and lengths; Provide equivalent mechanical performance (radial strength) to the best-in-class DES products.
Read More…

ABOUT

ABOUT

Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile.
The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. Read More…

WHAT WE DO

WHAT WE DO

Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile. Read More…

Latest News

TCT 2017 Poster Shows Impact of Strut Thickness on Thrombogenicity in BRS

ArterioSorb™ has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model.

Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of thrombus.

Shengjui, from Nicolas Foin’s group, compared thick strut BRS (157μm, Absorb BVS, Abbott Vascular) to thin strut BRS (95μm, ArterioSorb™, Arterius) and a thin strut DES (81μm, Xience, Abbott Vascular). Scaffolds were expanded in in-vitro coronary perfusion models which were perfused with porcine blood. Thrombus formation was then evaluated.

Thin strut ArterioSorb™ showed significantly smaller thrombus area compared to Absorb BVS (p<0.01).

No difference was found between thin strut ArterioSorb™ and Xience (p=0.99).

Summary: Compared to larger strut BRS, the thin strut ArterioSorb™ BRS and metallic DES show decreased acute platelet adherence and thrombus formation. The in-vitro model suggests that clot formation on scaffolds may be modulated by strut profile.

This further corroborates the previously published endothelial shear stress data showing less disruption to the arterial blood flow for ArterioSorb™ compared to Absorb BVS.

The full poster may be viewed here:TCT 2017 Strut Thickness Impact on Thrombogenicity in BRS